Sino Biopharmaceutical Limited announced that the latest results of phase II clinical study (NCT05383898) of KRAS G12C Inhibitor "Garsorasib Tablet (D-1553)", which is jointly developed by the Group, will be presented at the Annual Meeting 2024 of American Association for Cancer Research, for the treatment of patient with non-small cell lung cancer ("NSCLC") with KRAS G12C mutation. Title of abstract: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.09 HKD | -0.96% | -0.64% | -10.95% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.95% | 7.33B | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |
- Stock Market
- Equities
- 1177 Stock
- News Sino Biopharmaceutical Limited
- Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet